We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GE Healthcare Gets Priority Review for Molecular Imaging Agent

GE Healthcare Gets Priority Review for Molecular Imaging Agent

June 20, 2008

The FDA has accepted for priority review GE Healthcare’s NDA for imaging agent AdreView. The product’s action date is Sept. 20.

AdreView, which received orphan status in 2006, is a molecular imaging agent designed to help detect neuroendocrine tumors in children and adults.

Although GE Healthcare said it was difficult to estimate the number of U.S. patients with pheochromocytoma and neuroblastoma, it estimated there are 20,000–30,000 people with pheochromocytoma and 5,000 children with neuroblastoma. About 3,000 new diagnoses of pheochromocytoma occur annually, along with 650 neuroblastomas.

According to Cedars-Sinai Medical Center in Los Angeles, neuroendocrine tumors are rare and often misdiagnosed. Symptoms vary widely, and diagnosis is frequently determined only after the cancer has spread to other parts of the body. Advanced imaging and laboratory technology is used to identify such tumors in their earliest stages, the medical center said.

While granting the AdreView NDA priority review, the FDA encouraged GE Healthcare to institute an expanded access program for the product. The company said it expects a response from the FDA by July 9, if not sooner, on the protocol submitted for the program. The firm does not intend to charge patients for the drug.

Upcoming Events

  • 28Jun

    The Prediction Impact: Reduce Compliance Risks with Novel AI and ML Technology

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • SI-BONE Gets FDA Clearance for Its iFuse Bedrock Granite for Spinal Treatment

  • Sanofi and GSK Present Promising Data for Bivalent COVID-19 Vaccine

  • Aurora Spine Gets FDA Clearance for Spinal Fusion Device

  • Rexulti Shows Efficacy in Reducing Agitation in Alzheimer’s Patients

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing